Sera-Mag Select
Delivers selective binding of DNA fragments for use with next-generation sequencing (NGS) and PCR clean-up.
Variant
Overview
Combines the exceptional binding characteristics of Sera-Mag Carboxyl Speedbeads with an optimized binding solution in a ready-to-use formulation.
- Use a single reagent for PCR clean-up and size selection.
- Easily control what size DNA is retained or eliminated by adding various ratios of Sera-Mag Select to your sample. This enables NGS library and PCR fragment clean-up, as well as dual size selection of libraries.
- Uses the same protocols as existing reagents so can be directly integrated into existing workflows with minimal disruption.
- Sera-Mag Select delivers tight distribution in size selection for high yield recovery of specific fragment sizes.
- Suitable for manual, high throughput, and automated workflows.
- Sera-Mag Select should be stored in the refrigerator between 2°C to 8°C. Do not freeze. Store upright and keep bottle tightly sealed.
Find out which magnetic bead chemistry meets your application requirements in Magbeads 101: A guide to choosing and using magnetic beads and explore ways to optimize your magnetic bead workflow in Scientists guide to magnetic beads
The DNA size range isolated from the process can be tailored to suit the user’s end requirements by adjusting the amount of reagent that is mixed with a fixed volume of sample.
Request a free sample of Sera-Mag Select PCR clean-up and size selection reagent. Sera-Mag Select was developed with NGS in mind. Formulation can be customized and modified to meet your specific requirements.
Sera-Mag Select is used for the purification steps in a recent studyi: Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency.
Check out Cytiva Diagnostic Services, helping you build and accelerate the development of smarter molecular and immunodiagnostic assays.
Our ISO 13485 accredited manufacturing center of excellence adheres to the standards in the manufacturing process, ensuring the highest quality and compliance with international medical device regulations.
____
i Álvarez-Quilón, A., Terrón-Bautista, J., Delgado-Sainz, I. et al. Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency. Nat Commun 11, 910 (2020) https://creativecommons.org/licenses/by/4.0/
